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The circadian clock possesses robust systems to maintain the rhythm approximately
24 h, from cellular to organismal levels, whereas aging is known to be one of
the risk factors linked to the alternation of circadian physiology and behavior. The
amount of many metabolites in the cells/body is altered with the aging process, and
the most prominent metabolite among them is the oxidized form of nicotinamide
adenine dinucleotide (NAD+), which is associated with posttranslational modifications of
acetylation and poly-ADP-ribosylation status of circadian clock proteins and decreases
with aging. However, how low NAD+ condition in cells, which mimics aged or
pathophysiological conditions, affects the circadian clock is largely unknown. Here, we
show that low NAD+ in cultured cells promotes PER2 to be retained in the cytoplasm
through the NAD+/SIRT1 axis, which leads to the attenuated amplitude of Bmal1
promoter-driven luciferase oscillation. We found that, among the core clock proteins,
PER2 is mainly affected in its subcellular localization by NAD+ amount, and a higher
cytoplasmic PER2 localization was observed under low NAD+ condition. We further
found that NAD+-dependent deacetylase SIRT1 is the regulator of PER2 subcellular
localization. Thus, we anticipate that the altered PER2 subcellular localization by low
NAD+ is one of the complex changes that occurs in the aged circadian clock.
Keywords: circadian clock, PER2, NAD+, SIRT1, subcelluar localization
INTRODUCTION
The oxidized form of nicotinamide adenine dinucleotide (NAD+) found in all living cells plays
critical roles in a wide range of physiological processes. NAD+ acts as a coenzyme for enzymes
which are involved in energy metabolism and homeostasis pathways such as glycolysis, TCA cycle,
and oxidative phosphorylation (Campbell, 1995). NAD+ also acts as a co-substrate for enzymes
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such as sirtuins (SIRTs) and poly(ADP-ribose) polymerases
(PARPs) to regulate a wide array of cellular processes such
as survival/cell death, circadian clock, and aging (Imai and
Guarente, 2014; Verdin, 2015). In mammals, cellular NAD+ is
primarily biosynthesized by the NAD+ salvage pathway, in which
nicotinamide phosphoribosyltransferase (NAMPT) is the rate-
limiting enzyme and converts nicotinamide into nicotinamide
mononucleotide (NMN), the NAD+ precursor (Revollo et al.,
2007; Imai and Guarente, 2014; Nakahata and Bessho, 2016).
NAD+ amount declines during the aging process, causing
defects in nuclear and mitochondrial functions and resulting in
many age-associated diseases (Gomes et al., 2013; Mouchiroud
et al., 2013). Intriguingly, administration of NAD+ precursors
such as NMN and nicotinamide riboside (NR) can ameliorate
many age-associated pathologies, thereby leading to healthy
longevity (Yoshino et al., 2018; Custodero et al., 2020; Hong
et al., 2020). Similar to organismal aging, NAD+ amount is also
reported to decline with cellular aging, i.e., cellular senescence
(Khaidizar et al., 2017). Overexpression of NAMPT in primary
fibroblast cells delays the onset of replicative senescence (van der
Veer et al., 2007; Khaidizar et al., 2017) and confers a protective
effect against stress-induced premature senescence (Nuriliani
et al., 2020). These reports demonstrate that a decline in NAD+
is one of the causes to induce cellular senescence as well as
organismal aging.
NAD+ in cells and organs demonstrates circadian oscillation
due to the circadian clock regulation of Nampt gene expression
(Nakahata et al., 2009; Ramsey et al., 2009). Moreover, NAD+
is associated with the transcriptional regulation of circadian
clock genes through the regulation of SIRT1, SIRT6, and PARP1
activities (Asher et al., 2008, 2010; Nakahata et al., 2008; Masri
et al., 2014). These findings demonstrate that circadian clock
and NAD+ metabolism are mutually regulated (Imai, 2010;
Nakahata and Bessho, 2016). Since NAD+ amount declines with
senescence/aging, circadian clock properties are expected to be
altered by senescence/aging. Indeed, circadian clocks in primary
cells, tissues, and animals show altered circadian properties by
senescence/aging. The circadian amplitude at the transcriptional
(Kunieda et al., 2006; Nakamura et al., 2015; Ahmed et al.,
2019), neural activity (Nakamura et al., 2011), and locomotor
activity levels (Pittendrigh and Daan, 1974; Witting et al., 1994;
Valentinuzzi et al., 1997; Sellix et al., 2012) declines with aging.
The period of circadian genes alters with senescence/aging
in primary human fibroblasts and ex vivo mouse SCN slices
(Nakamura et al., 2015; Ahmed et al., 2019), although it is still
controversial at the organismal level (Valentinuzzi et al., 1997;
Aujard et al., 2001; Kolker et al., 2004). However, only a few
researches have looked into the molecular mechanisms of how
the circadian clock is affected by senescence/aging (Chang and
Guarente, 2014; Zwighaft et al., 2015; Levine et al., 2020).
We have reported that a decline in NAD+ keeps activating
the transcription of E-box-regulated circadian clock genes via
hyperacetylation of lysine 9/14 residues on histone H3, due to the
inactivation of NAD+-dependent deacetylase, SIRT1 (Nakahata
et al., 2008). In addition to that report, some investigators
have also demonstrated that NAD+ regulates other circadian
clock components: SIRT1 deacetylates PER2, resulting in its
stabilization (Asher et al., 2008); SIRT1 deacetylates PGC1α to
activate Bmal1 transcription (Chang and Guarente, 2014); PARP-
1, an NAD+-dependent ADP-ribosyltransferase, poly(ADP-
ribosyl)ates CLOCK (Asher et al., 2010); and the inhibitor
of SIRT1 changes the ratio of PER2 subcellular localization
(Miki et al., 2012).
The aforementioned findings prompted us to reveal the
molecular mechanisms of how NAD+ amount, especially low
NAD+, affects the circadian clock system, which might give
some hints to unravel molecular links between aging and
circadian clock. In this study, we reduced intracellular NAD+
amount by inhibiting NAMPT enzymatic activity and found
that it attenuates the amplitude of Bmal1 promoter-driven
luciferase oscillation and promotes cytoplasmic localization of
PER2, leading to attenuated CRY/PER-dependent repression,
thereby enhancing E-box-regulated circadian gene expressions.
At the molecular level, we revealed that the translocation of
PER2 with low NAD+ is dependent upon SIRT1 activity, but
not PARP1 activity.
MATERIALS AND METHODS
Reagents, Antibodies, and Plasmids
FK866, GMX1778, nicotinamide, EX-527, and PJ34 were
purchased from the Axon Medchem, AdipoGen Life
Sciences, Sigma, Cayman Chemical, and Abcam, respectively.
Nicotinamide mononucleotide (NMN) was provided by the
Mitsubishi Corporation Life Sciences Limited, Japan. Anti-Per2
(PM083), anti-Lamin B1 (PM064), anti-Myc-tag (M047-
3), and anti-DDDDK-tag (M185-3) were purchased from
the MBL, Japan. Anti-α-tubulin (T6074) and the secondary
anti-mouse antibody Alexa Fluor Plus 488 (A32723) were
purchased from the Sigma-Aldrich and Thermo Fisher Scientific,
respectively. PAR/pADPr antibody was purchased from
the R&D Systems. Anti-Bmal1 (ab93806) and anti-acetyl
Bmal1 (Lys538) were purchased from the Abcam and Merck,
respectively. Secondary anti-mouse (NA931V) or rabbit (NA934)
antibodies conjugated with HRP were purchased from the
GE Healthcare. Myc-mClock/pcDNA3 was subcloned from
Myc-mClock/pSG5 as described (Doi et al., 2006). 5xMyc-
mCry1-Flag/pCS2 and Myc-mBmal1/pcDNA3 were described
as previously (Hirayama et al., 2007). Flag-hRORα1/pcDNA3,
Flag-hRORγ/pcDNA3, Flag-mRev-erbα/pcDNA3, and Flag-
mRev-erbβ/pcDNA3 were inserted a single Flag epitope into
hRORα1/pcDNA3, hRORγ/pcDNA3, mRev-erbα/pcDNA3,
and mRev-erbβ/pcDNA3, respectively, provided by Akashi
and Takumi (2005). Flag-mCry1/pcDNA3, 2xMyc-Per2-
NLS/pcDNA3, and 2xMyc-Per2-NES/pcDNA3 were kind gifts of
Akashi et al. (2014). pLLX-shRNA and pLLX-scrambled shRNA
were kindly provided by ME Greenberg (Zhou et al., 2006).
Cell Culture
NIH3T3 cells were cultured in DMEM–4.5 g/L glucose (Nacalai
Tesque, Japan) supplemented with 10% FBS (Sigma) and
antibiotics (100 units/ml penicillin, 100 µg/ml streptomycin,
Nacalai Tesque, Japan) at 37◦C and 5% CO2 in a humidified
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incubator. Cells were treated with FK866/GMX1778 with or
without 1 mM nicotinamide mononucleotide for 24 h and
harvested for measuring NAD+ amount, performing qPCR,
immunofluorescence, and western blotting. For experiments
analyzing circadian oscillations of clock genes, luciferase, and
PER2 protein, cells were pretreated with FK866 for 24 h
before Dex synchronization and also treated with FK866 after
synchronization.
Quantification of Intracellular NAD+ by
HPLC
NAD+ was measured by an HPLC system, an Agilent
1260 Infinity Binary LC System with guard (Polaris C18-A,
MetaGuard, 5 µm, 4.6 mm; A2000MG, Agilent) and analytical
(Polaris 5 C18-A 4.6 × 150 mm; A2000150 × 046, Agilent)
columns, following the protocol reported previously (Yoshino
and Imai, 2013; Khaidizar et al., 2017).
SDS-PAGE, Western Blotting Analysis,
RNA Extraction, and qPCR
Protocols for SDS-PAGE, western blotting analysis, RNA
extraction, and qPCR were followed as described previously
(Khaidizar et al., 2017). Protein measurement was performed
using 660 Protein Assay Reagent (Thermo Fisher Scientific)
according to the manufacturer’s instruction. The sequences for
qPCR primers are shown in Supplementary Table 1.
Real-Time Luciferase Monitoring Assay
The method was described previously (Ahmed et al., 2019).
Immunofluorescence
NIH3T3 cells were seeded on a sterilized cover glass (Matsunami;
24 × 24 mm; thickness no. 1) placed on a six-well plate so as
to have 4 × 105 cells/well as a single experiment. Cells were
co-transfected with indicated expression vectors using FuGENE
HD (Promega) and cultured for 48 h. The cells after washing
twice with phosphate buffered saline (PBS) were fixed with
1 ml of 4% paraformaldehyde for 15 min with shaking at
room temperature. Then, cells were washed three times with
PBS and permeabilized with 1 ml of 0.5% Triton X-100 for
10 min with shaking at room temperature. After blocking the
cells with 1% bovine serum albumin (BSA) for 30 min at room
temperature, the cells were washed three times with PBS and
incubated with Myc antibody diluted with 1% BSA/PBS for 1 h
at room temperature. Then, cells were incubated with secondary
antibody conjugated with Alexa Fluor Plus 488 diluted with
1% BSA/PBS for 1 h at room temperature. Nuclei were also
stained with 1 µg/ml Hoechst 33342 (Nacalai Tesque, Japan)
to justify subcellular localizations of clock proteins. Fluorescent
images were acquired with a confocal laser scanning microscope
(ZEISS; LSM 700), and subcellular localizations of clock proteins
were counted at least 100 cells. We interpreted the result
for nuclear localization of PER2/CRY1 (N) as positive when
fluorescence intensity of PER2/CRY1 signal that overlapped with
Hoechst 33342 signal was higher than the fluorescence intensity
of PER2/CRY1 in the cytoplasm (Supplementary Figure 1).
Meanwhile, we interpreted the result for cytoplasmic localization
of PER2/CRY1 (C) as positive when PER2/CRY1 signal that
did not overlap with Hoechst 33342 signal exhibited higher
fluorescence intensity than PER2/CRY1 signal intensity that
overlapped with Hoechst 33342 signal. Finally, we interpreted
the result for nuclear and cytoplasm localization of PER2/CRY1
(N+ C) as positive when PER2/CRY1 fluorescence signal at both
nucleus and cytoplasm had the same intensities. We performed
the experiments independently for at least three times and
showed the data as mean± SEM.
Nuclear Extract From NIH3T3 Cells
NIH3T3 cells treated with or without 7.5 nM FK866 for 24 h in a
10-cm dish were synchronized with 100 µM dexamethasone for
1 h. Synchronized cells after 24–44 h were collected every 4 h.
Cells were washed twice with PBS and harvested by cell scrapers,
centrifuged at 300× g for 5 min at 4◦C, and resuspended in 50 µl
lysis buffer [10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM
KCl]. Cells were vortexed for 10 s and allowed to stand on ice
for 10 min, and the same step was repeated again to extract cell
components other than the nuclear fraction. The nuclear fraction
was washed three times with lysis buffer, added with 50 µl RIPA
buffer [50 mM Tris–HCl (pH 7.4), 150 mM NaCl2, 1 mM EDTA,
0.2% SDS, 1% NP-40], vortexed for 30 s, and then allowed to
stand on ice for 20 min. The nuclear fraction was centrifuged at
15,000 × g for 5 min at 4◦C, and the supernatant was collected
as a nuclear extract. Total cell extract was obtained by extracting
cells with RIPA buffer.
Dual-Luciferase Promoter Assay
NIH3T3 cells seeded in a 24-well plate were co-transfected
with 500 ng of Per1 firefly reporter, 50 ng of EF1a Renilla
reporter, and indicated expression vectors using FuGENE
HD (Roche). Samples were prepared using a Dual-Luciferase
promoter assay kit (Promega) according to their instructions and
analyzed by a multiwell luminescence measurement plate reader
(Mithras, LB940). Firefly luciferase activity of the reporter was
normalized by the activity of Renilla luciferase under control of
EF1α promoter.
Establishment of Sirt1 Knockdown Cell
To establish Sirt1 knockdown cells, lentivirus vector pLLX-
shRNA (Zhou et al., 2006), which expresses GFP and a
puromycin resistant gene, was used. After virus infection to
Bmal1-luc/NIH3T3 (Yoshitane et al., 2012), cells were selected
by puromycin for 1 week and confirmed by GFP fluorescence
(all cells were ∼100% GFP positive). Three different target
sequences for mouse Sirt1 and scramble sequence are shown in
Supplementary Table 2.
Statistics
Values are reported as mean ± SEM. Statistical differences were
determined by a Student’s two-tailed t-test. Statistical significance
is displayed as ∗p < 0.05, ∗∗p < 0.01, or ∗∗∗p < 0.001.
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RESULTS
To investigate how the circadian clock system is affected by
low NAD+ in cells, we first evaluated how much NAD+
was decreased by the inhibition of the rate-limiting enzyme,
NAMPT, in the NAD+ salvage pathway (Figure 1A). We used
FK866 (Hasmann and Schemainda, 2003) to inhibit the NAMPT
activity and found that 2.0, 5.0, and 7.5 nM FK866 treatment
decreased NAD+ to approximately 50, 33, and 25%, respectively
(Figure 1B). In addition, the acetylated form of BMAL1, which
has been reported to be increased by FK866 treatment (Nakahata
et al., 2009), was increased by FK866 treatment in a dose-
dependent manner (Supplementary Figure 2A). We further
confirmed that the effect of FK866 treatment at 7.5 nM on
NAD+ amount was abrogated by the co-treatment with the
NAD+ precursor, NMN (Figure 1C). A similar tendency was
observed by another NAMPT inhibitor, GMX1778 (Watson et al.,
2009) (Supplementary Figures 3A,B). We then performed a
real-time luciferase assay to address whether circadian clock
properties are affected by low NAD+. To address that, we
used NIH3T3 cells stably expressing Bmal1 promoter-driven
luciferase (Yoshitane et al., 2012). The amplitude, which was
defined in this study as the height from the first peak to the
first trough, of Bmal1 promoter-driven luciferase oscillation
was attenuated in FK866-treated cells, compared with that
in control cells (Figures 1D,E). A delayed phase was also
observed in FK866-treated Bmal1-luc oscillation. Intriguingly,
the attenuated amplitude and delayed phase were abrogated in
FK866 and NMN co-treated cells, indicating that the amplitude
and phase are regulated by NAD+ amount. The reason why
these alterations were abrogated after 60 h Dex treatment is
presumably due to the recovery of intracellular NAD+ amount
(Supplementary Figure 4). We further checked endogenous
circadian gene expressions in unsynchronized cells with low
NAD+. Among core circadian genes, E-box-regulated genes,
such as Rev-erbα, Rev-erbβ, Per1, and Per2, were upregulated;
however, the RORE-regulated gene, Bmal1, was downregulated
(Figure 1F). Moreover, these alterations were abrogated in FK866
and NMN co-treated cells, indicating that the alterations of
these genes are regulated by NAD+ amount. Furthermore, we
demonstrated that circadian profiles of endogenous Bmal1 and
Rev-erbα transcripts were also affected, lower Bmal1 and higher
Rev-erbα, in synchronized cells with low NAD+ (Figure 1G).
These results demonstrate that low NAD+ alters transcript levels
of not only E-box-regulated genes as we have reported previously
(Nakahata et al., 2008), but also RORE-regulated genes, which
presumably regulate the amplitude of circadian clocks.
As our previous studies have demonstrated that the circadian
gene expressions are epigenetically regulated by NAD+-
dependent deacetylases, SIRT1 and SIRT6 (Nakahata et al.,
2008; Masri et al., 2014), in this study, we sought to find out
whether the properties of circadian clock proteins, such as protein
stability and subcellular localization, are regulated by NAD+
amount. First, whether low NAD+ affects protein stability of
clock proteins was investigated using cycloheximide, which is
an inhibitor of protein biosynthesis due to its prevention in







FIGURE 1 | FK866 changes the expression levels of circadian genes, which is
abrogated by co-treatment with NMN. (A) Scheme of the NAD+ salvage
pathway. NAM, nicotinamide; NMN, nicotinamide mononucleotide; NAMPT,
nicotinamide phosphoribosyltransferase; NMNAT1-3, nicotinamide
mononucleotide adenylyltransferase 1-3. (B) NAD+ amount after 24 h
treatment of FK866 at indicated concentrations was measured by HPLC.
NAD+ amount was normalized by protein amount. (C) NAD+ amount after
24 h treatment of 7.5 nM FK866 with or without 1 mM NMN was measured
by HPLC. NAD+ amount was normalized by protein amount. (D) Bmal1-luc
oscillation patterns in NIH3T3 cells treated with FK866 with or without NMN
were monitored by using a real-time luciferase monitoring system. One
representative result is shown for each condition. (E) Relative amplitudes were
analyzed. In this study, the amplitude was defined as the height from the first
peak to the first trough. The value of control (ctrl) was set to 1. (F) Circadian
gene expression levels after treatment with 7.5 nM FK866 alone or 7.5 nM
FK866 and 1 mM NMN were quantified by qPCR. Each sample was
normalized by the amount of 18S rRNA. Each gene expression level in
untreated cells (ctrl) was set to 1. (G) Circadian profiles of Bmal1 and
Rev-erbα synchronized by DEX were quantified. Each sample was normalized
by 18S rRNA. Time 12 of control cells was set to 1 for each gene. All data
represented here, except (E) (n = 4), are the mean ± SEM of three
independent samples. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, compared to
each of the untreated control by Student’s two-tailed t-test.
BMAL1, PER2, and CRY1 were not significantly affected by low
NAD+ (Supplementary Figure 5). Next, whether low NAD+
affects subcellular localization of clock proteins was investigated
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FIGURE 2 | FK866 changes PER2 subcellular localization, which is abrogated by co-treatment with NMN. [(A–D), top] NIH3T3 cells expressing Myc-PER2 (A),
Myc-CRY1-Flag (B), or Myc-PER2/Flag-CRY1 (C) were immunostained with antibody to Myc or Flag (top). Cells were either untreated (ctrl) or treated with 7.5 nM
FK866 (FK) or 7.5 nM FK866 and 1 mM NMN (FK + NMN). NIH3T3 cells expressing Flag-CRY1 and either Myc-PER2-WT, Myc-PER2-NLS, or Myc-PER2-NES were
immunostained with antibody to Flag (D). The representative images were captured by a confocal laser scanning microscope. White scale bars represent 100 µm.
[(A–D), bottom] Subcellular localizations were counted and quantified; N, nucleus; C, cytoplasm; N + C, both nucleus and cytoplasm. The data represented are the
mean ± SEM of at least three independent samples. ∗p < 0.05, ∗∗p < 0.01, compared to each subcellular localization in control cells by Student’s two-tailed t-test.
(E) PER2 protein levels in nuclear extract and total cell lysate were detected under the 7.5 nM FK866-treated condition (top). PER2 protein levels were quantified
using ImageJ software (bottom). Each sample was normalized by LAMIN B1 protein level. TUBULIN was used to confirm fractionation. The data represented as filled
circle and triangle are individual data of two independent samples and bars are the average of two samples.
(Figures 2A,B and Supplementary Figure 6). Among clock
proteins tested in this study, subcellular localization of PER2 was
clearly affected by FK866 treatment (Figure 2A). Cytoplasmic
and nuclear PER2 under control condition were 18.8 ± 3.4 and
49.3± 4.2%, respectively, whereas cytoplasmic and nuclear PER2
under FK866-treated condition were 32.0± 7.9% (p = 5.1× 10−3,
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compared with cytoplasmic PER2 under control condition)
and 34.5 ± 9.2% (p = 3.8 × 10−3, compared with nuclear
PER2 under control condition), respectively. Furthermore,
GMX1778 treatment also changed the ratio of PER2 subcellular
localization from 22.2 ± 0.5 to 26.3 ± 0.1% in the cytoplasm
(p = 1.0 × 10−4) and from 62.0 ± 1.9 to 50.0 ± 0.6%
in the nucleus (p = 2.0 × 10−4) (Supplementary Figure 7).
Importantly, the effect of FK866 or GMX1778 on PER2
subcellular localization was abrogated when cells were treated
with both FK866 and NMN or GMX1778 and NMN (Figure 2A
and Supplementary Figure 7). These results indicate that PER2
subcellular localizations are controlled by intracellular NAD+
amount; lower NAD+ promotes the translocation of PER2 from
the nucleus to the cytoplasm. Similarly, cytoplasmic and nuclear
CRY1 under control condition were 6.3 ± 0.9 and 75.6 ± 3.9%,
respectively, while cytoplasmic and nuclear CRY1 under FK866-
treated condition were 10.6 ± 2.8% (p = 0.026, compared with
cytoplasmic CRY1 under control condition) and 67.1 ± 8.5%
(p = 0.12, compared with nuclear CRY1 under control condition),
respectively (Figure 2B), indicating the similarity to the change
in PER2 by FK866 treatment. These results prompted us to
investigate whether the increase in PER2 cytoplasmic localization
triggered by FK866 induces the increase in CRY1 cytoplasmic
localization, because it is well known that PER2 determines CRY1
localization (Albrecht et al., 2007). Cytoplasmic localizations of
CRY1 co-expressing PER2 with or without FK866 were 15.4± 0.7
and 10.8 ± 0.8% (p = 4.8 × 10−3) and nuclear localizations
were 71.8 ± 2.2 and 81.7 ± 1.3% (p = 8.6 × 10−3), respectively
(Figure 2C). The alteration of CRY1 subcellular localization
by FK866 treatment was more when PER2 was co-expressed,
suggesting that the alteration of PER2 subcellular localization
leads to that of CRY1.
To confirm whether the changes in PER2 subcellular
localization alter CRY1 subcellular localizations, PER2 wild type
(WT), C-terminal-tagged nuclear localization signal (-NLS), or
C-terminal-tagged nuclear export signal (-NES) (Akashi et al.,
2014) was co-expressed with CRY1. Similar to a previous report
(Akashi et al., 2014), nuclear localizations of PER2-WT, PER2-
NLS, and PER2-NES without CRY1 were 59.1 ± 2.1, 73.6 ± 1.3,
and 37.0 ± 4.7%, respectively (Supplementary Figure 8A). As
expected, subcellular localizations of CRY1 were followed by
those of PER2. Compared with the ratio of nuclear CRY1 co-
expressing with PER2-WT (73.1 ± 1.6%), the ratio of nuclear
CRY1 was increased (81.1 ± 0.7%, p = 0.011) when PER2-
NLS was co-expressed, whereas the ratio of nuclear CRY1 was
decreased (59.8 ± 2.2%, p = 0.008) when PER2-NES was co-
expressed (Figure 2D). These results are consistent with previous
reports that PER2 determines CRY1 localization (Albrecht et al.,
2007). Even when CRY1 was co-expressed with these PER2s,
PER2 subcellular localizations were not affected (Supplementary
Figure 8B). The results of Figures 2A–D suggest that localization
of PER2 is directly affected by intracellular NAD+ amount and
the intracellular localization of CRY1 follows that of PER2.
Since PER2 protein amount and subcellular localization show
time-of-day variations, whether circadian subcellular localization
of PER2 is affected by NAD+ amount was next investigated
(Figure 2E). Although nuclear localization of PER2 clearly
showed the time-of-day variation under the control condition
as reported previously (Lee et al., 2001; Yagita et al., 2001),
the nuclear accumulation of PER2 was reduced, but still
showed circadian oscillation, under the FK866-treated condition
(Figure 2E, left panel). Intriguingly, PER2 in total cell lysate
under the FK866-treated condition was comparable with that
under the control condition (Figure 2E, right panels), suggesting
that the reduction of PER2 nuclear localization under the FK866-
treated condition is not due to the reduction of PER2, but
the decrease in PER2 nuclear entry and/or the increase in
PER2 nuclear export.
CRY acts as a transcriptional repressor with PER against
CLOCK/BMAL1-dependent, namely E-box-regulated,
transcriptions. As the decrease in nuclear localization of PER2
by FK866 suggested the attenuation of PER/CRY-dependent
repression against E-box-regulated genes, we next addressed
that possibility. To address that, luciferase reporter assay using
Per1 promoter that possesses several E-boxes was assessed
using PER2-NES, which mimics PER2 subcellular localizations
under the FK866-treated condition. As reported previously,
Per1 promoter activity was activated by CLOCK/BMAL1
and this activation was repressed by CRY1 (Figure 3). When
PER2-NES was co-expressed, the repression by CRY1 against
CLOCK/BMAL1-dependent Per1 expression was attenuated;
namely, the luciferase intensities were increased in a PER2-NES
dose-dependent manner (Figure 3). On the other hand, when
PER2-WT or PER2-NLS was co-expressed, the repression
by CRY1 was not affected. The results from Figures 2E, 3
indicate that PER2 subcellular localization determines PER/CRY-
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FIGURE 3 | PER2 subcellular localization affects Per1 gene expression. The
effects of PER2-WT, PER2-NLS, and PER2-NES on per1 luciferase activity are
shown; 100 ng of CLOCK, 100 ng of BMAL1, 10 ng of CRY1, 500 ng of Per1
firefly reporter, and 50 ng of EF1a Renilla reporter were co-transfected in
NIH3T3 cells. Indicated amounts of PER2-WT, PER2-NLS, or PER2-NES
were also co-transfected in NIH3T3 cells. Firefly luciferase intensity was
normalized by Renilla luciferase intensity. Basal per1 promoter activity (far left
bar) was set to 100. The data represented are the mean ± SEM of three
independent samples. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, compared
with the sample with CLOCK/BMAL1 and CRY1, the third bar from left, by
Student’s two-tailed t-test.
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of upregulation of E-box-regulated genes under the FK866-
treated condition (Figure 1C) is due to the preferential
cytoplasmic localization of PER2 with CRY1.
Finally, to investigate the molecular mechanisms of how
PER2 subcellular localization is regulated, we pharmacologically
inhibited NAD+-dependent enzymes, SIRT1 and PARP1. The
SIRT1 inhibitors, 10 mM nicotinamide (NAM) or 5 µM EX-
527 (Bitterman et al., 2002; Napper et al., 2005), significantly
increased cytoplasmic PER2 from 24.1 ± 1.3 to 39.5 ± 0.5%
(p = 4.0 × 10−4) and 33.5 ± 2.1% (p = 1.9 × 10−4), respectively,
and decreased nuclear PER2 from 42.7 ± 5.5 to 28.7 ± 3.8%
(p = 3.0 × 10−4) and 30.5 ± 4.2% (p = 1.8 × 10−4), respectively
(Figure 4A), showing the same tendency when treated by
FK866 (Figure 2A). Both 10 mM NAM and 5 µM EX-527
were confirmed to be effective to inhibit SIRT1 deacetylate
activity against BMAL1 (Nakahata et al., 2008; Supplementary
Figures 2A,B). However, the PARP1 inhibitor, PJ34 (Abdelkarim
et al., 2001), did not change both cytoplasmic and nuclear
PER2 populations [17.3 ± 3.8% (p = 0.56) and 54.6 ± 3.3%
(p = 0.10), respectively] (Figure 4), and even 10 µM PJ34
was confirmed to be effective to reduce poly-ADP-ribosylation
(Supplementary Figure 2C). As FK866 treatment attenuated
the amplitude of Bmal1-luc circadian oscillation (Figures 1D,E),
we further investigated whether SIRT1 deacetylation activity
is involved in the regulation of amplitude of Bmal1-luc
circadian oscillation. NAM or EX-527 treatment attenuated the
amplitude of Bmal1-luc circadian oscillation (Figures 4B,C,E).
Intriguingly, a delayed phase was observed only in cells
treated with 10 mM NAM, the concentration at which the
enzymatic activity of SIRT1 and also others such as SIRT2
and PARP1 is inhibited (Virág and Szabó, 2002; Peck et al.,
2010). However, a delayed phase was not observed in cells
treated with 5 µM EX-527, the concentration at which the
enzymatic activity of SIRT1 is specifically inhibited (Peck et al.,
2010), suggesting that SIRT1 deacetylation activity is involved
in the amplitude regulation and other enzymes inhibited by
NAM are involved in the phase regulation. Sirt1-knockdown
cells also demonstrated the attenuated Bmal1-luc amplitude,
but not a delayed phase (Figure 4D). Knockdown efficiencies
against Sirt1 and circadian oscillation patterns of other Sirt1
knockdown cell lines are shown in Supplementary Figure 9.
These results demonstrate that the NAD+/SIRT1 axis regulates
PER2 subcellular localization, which further affects the amplitude
of the circadian clock.
To further investigate whether the acetylation status of lysine
680 residue of PER2, where PER2 is acetylated and deacetylated
by SIRT1 (Levine et al., 2020), affects its subcellular localization,
we analyzed subcellular localizations of lysine 680 residue
mutants of PER2 (Figure 5). Non-acetyl mimetic PER2K680R
mutant only slightly increased in the cytoplasmic population of
PER2, compared with the cytoplasmic population of PER2WT
(p = 0.010). Moreover, acetyl mimetic PER2K680Q had no effect on
PER2 subcellular localization. These mutant PER2 experiments
suggest that K680 of PER2 is not the responsible lysine to regulate
subcellular localization by SIRT1, although we cannot deny the
possibility that acetyl mimetic mutant of PER2K680Q does not
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FIGURE 4 | SIRT1 inhibitors, but not PARP1 inhibitor, regulate PER2
localization and attenuate the amplitude. (A) NIH3T3 cells expressing
Myc-PER2 were immunostained with antibody to Myc. Cells were either
untreated (ctrl), treated with 10 mM nicotinamide (NAM), 5 µM EX-527 or
10 µM PJ34 (top). The representative images were captured by a confocal
laser scanning microscope. White scale bars represent 100 µm. (Bottom)
Subcellular localizations were quantified; N, nucleus; C, cytoplasm; N + C,
both nucleus and cytoplasm. The data represented are the mean ± SEM of
independent three samples. ∗∗∗p < 0.001, compared to each subcellular
localization in control (ctrl) cells by Student’s two-tailed t test. (B,C) Bmal1-luc
oscillation patterns in NIH3T3 cells treated with either NAM or EX-527 were
monitored by using a real-time luciferase monitoring system. One
representative result is shown for each condition. (D) Bmal1-luc oscillation
patterns in WT (ctrl) or Sirt1 knockdown (shSirt1 #3) NIH3T3 cells were
monitored by using a real-time luciferase monitoring system. One
representative result is shown for each condition. (E) Relative amplitudes were
analyzed. The value of control (ctrl) was set to 1. The data represented are the
mean ± SEM of independent 8, 5, 3 or 3 samples for the control, NAM,
EX-627, or shSirt1 #3, respectively. ∗p < 0.05, ∗∗p < 0.01, compared to the
control (ctrl) by Student’s two-tailed t-test.
DISCUSSION
In this study, we found that low intracellular NAD+, which
was induced by the pharmacological inhibition of NAMPT,
promoted PER2 subcellular localization from the nucleus to the
cytoplasm and increased and decreased the expressions of E-box-
and RORE-regulated circadian genes, respectively, leading to
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FIGURE 5 | PER2K 680 mutants have no effects on PER2 subcellular
localizations. NIH3T3 cells expressing either Myc-PER2-WT (WT),
Myc-PER2K 680R (KR) or Myc-PER2K 680Q (KQ) were immunostained with
antibody to Myc (top). The representative images were captured by a confocal
laser scanning microscope. White scale bars represent 100 µm. (bottom)
Subcellular localizations were quantified; N, nucleus; C, cytoplasm; N + C,
both nucleus and cytoplasm. The data represented are the mean ± SEM of
three independent samples. ∗p < 0.05, compared to each subcellular
localization in WT cells by Student’s two-tailed t-test.
the attenuated Bmal1-luc circadian oscillation. Furthermore, we
demonstrated that SIRT1 was responsible for NAD+-dependent
PER2 subcellular regulation, and suggested that lysine 680
residue on PER2 is not responsible for SIRT1-regulated PER2
subcellular localization.
Since several lines of evidence indicate that a decline in NAD+
is a hallmark of senescence/aging (Braidy et al., 2011; Yoshino
et al., 2011; Canto et al., 2012; Massudi et al., 2012; Camacho-
Pereira et al., 2016; Zhang et al., 2016; Khaidizar et al., 2017),
in this study, we used NAMPT inhibitors, FK866 and GMX1778,
to reduce intracellular NAD+, which, we expect, mimics cellular
senescence. However, many other physiological events and
metabolites such as AMP/ATP ratio and polyamines are known
to be changed with senescence/aging (James et al., 2015; Zwighaft
et al., 2015). An increase in the AMP/ATP ratio promotes
AMP-activated protein kinase (AMPK), which acts as a sensor
of the reduced energetic state and further activates catabolic
pathways while inhibiting anabolic ones (Hardie, 2003; Garcia
and Shaw, 2017). Meanwhile, it has been reported that mTOR,
which is an intracellular nutrient sensor for high cellular energy
state and associated with autophagy, is also upregulated during
senescence (Herranz et al., 2015; Laberge et al., 2015; Nacarelli
and Sell, 2017). These signaling molecules have been reported
to be involved in the circadian clock. AMPK is a rhythmically
expressed kinase and phosphorylates CK1ε, resulting in enhanced
phosphorylation and degradation of PER2 (Um et al., 2007;
Sahar and Sassone-Corsi, 2012) and CRY1 (Lamia et al., 2011;
Sahar and Sassone-Corsi, 2012; Jordan and Lamia, 2013). mTOR
perturbation, such as RNAi knockdown or mTOR inhibitors,
alters circadian rhythms in fibroblast, SCN, and animal behaviors
(Zhang et al., 2009; Ramanathan et al., 2018). Several lines of
evidence mentioned here imply that the altered aforementioned
signaling pathways during senescence may affect circadian
clock properties, although it is largely unknown whether these
pathways alter circadian clock properties in senescent cells. We
recently demonstrated that altered circadian properties such as
period extension and phase delay occur in senescent human cells
(Ahmed et al., 2019, 2021). Therefore, we assume that these
circadian alterations in senescent cells will be useful indexes to
evaluate whether low NAD+ or other conditions are sufficient for
the circadian clock to mimic senescent condition.
Real-time luciferase monitoring assay revealed that the
attenuated amplitude of Bmal1-luc oscillations was observed by
either NAMPT inhibitors, FK866 and GMX1778; Sirtuins and
PARPs broad inhibitor, NAM; SIRT1-specific inhibitor, EX-527;
or Sirt1 knockdown. However, the delayed phase of Bmal1-
luc oscillations was not observed by SIRT1-specific inhibitor,
EX-527, or Sirt1 knockdown. These results indicate that SIRT1
deacetylation activity is involved in amplitude regulation, but
not in phase regulation. This is supported by the report that
circadian profiles of Dbp and Per2 in Sirt1−/− cells showed
higher amplitude and no delayed phase (Nakahata et al., 2008). In
contrast, delayed phases were observed with FK866, GMX1778,
or NAM treatment, suggesting that NAD+-dependent enzymes
other than SIRT1 are involved in the phase regulation. The
investigation to address which enzyme is associated with phase
regulation will be needed to understand the mechanisms
of how circadian clocks work in senescent cells. Actually,
we have recently shown that senescent cells possess altered
circadian clocks with a prolonged period and delayed phase
(Ahmed et al., 2019, 2021).
In this study, we investigated whether acetylation of lysine 680
residue on PER2 is responsible for PER2 subcellular localization;
however, neither acetyl mimetic mutant (K680Q) nor non-
acetyl mimetic mutant (K680R) of PER2 changed subcellular
localization such as low NAD+ or SIRT1 inhibitor-treated
conditions. Levine and coworkers recently reported that PER2 is
acetylated on K680, which is deacetylated by SRIT1; furthermore,
FK866 treatment increases PER2 phosphorylation at numerous
sites (Levine et al., 2020). This suggests that acetylation of K680
or other lysine residues of PER2 might be a trigger for subsequent
phosphorylation(s), which might determine PER2 subcellular
localization. Our current results cannot deny the possibility that
acetyl mimetic mutant PER2K680Q may not trigger subsequent
phosphorylation(s) because of differences of three-dimensional
structures triggered by the acetylated form of lysine residue and
substituted glutamine residue. Further experiments including
structural biological experiments will be needed to elucidate
which lysine residue is responsible for subcellular localization of
PER2 regulated by SIRT1.
Our current results suggest that PER/CRY-dependent
repression against E-box-regulated genes might be dependent
on the NAD+/SIRT1 axis. Intriguingly, we have reported
that SIRT1 deacetylates lysine 9/14 residues of histone H3
on the promoters of E-box-regulated genes to repress their
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expressions epigenetically (Nakahata et al., 2008). These results
imply that the NAD+/SIRT1 axis coordinates the transcriptional
repression of E-box-regulated genes by different ways. In
addition to the coordinated mechanisms for E-box-regulated
genes, RORE-regulated genes might also be coordinated by the
NAD+/SIRT1 axis. It has been reported that NAD+ activates
Bmal1 transcription by SIRT1 through the deacetylation of
PGC1α (Chang and Guarente, 2014), while we demonstrated
in this study that the low NAD+ condition increased Reb-
erbα/β which in turn might repress Bmal1 gene expression.
These coordinated Bmal1 gene regulations by the NAD+/SIRT1
axis presumably regulate the amplitude of Bmal1 circadian
oscillation, namely the low NAD+ condition or decreased SIRT1
activity attenuates the amplitude of Bmal1 circadian oscillation.
Therefore, these coordinated transcriptional regulations of
E-box- and RORE-regulated circadian genes by the NAD+/SIRT1
axis might interlock circadian negative feedback loops.
In addition to our finding that low NAD+ retains PER2
in the cytoplasm, some studies have demonstrated that
the NAD+/SIRT1 axis regulates PER2 properties; PER2 in
Sirt1−/− cells is more stable (Asher et al., 2008) and localizes
predominantly in the nucleus (Levine et al., 2020), while PER2
in nicotinamide-treated cells localizes predominantly in the
cytoplasm (Miki et al., 2012). Our pharmacologically conducted
results were consistent with the results pharmacologically
performed by Miki and colleagues, but not with the
results performed genetically. These conflicting results by
pharmacological (acute) and genetical (chronic) approaches
suggest the possibility that responses of molecular clock are
different at early and chronic senescence/aging phases. This
possibility is worth verifying so further experiments using
different stages of senescent cells/aging animals will be needed
to reveal this possibility.
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Supplementary Figure 1 | Representative Immunofluorescence images. N,
nucleus; C, cytoplasm; N + C, nuclear and cytoplasm. We interpreted a result for
nuclear localization of PER2/CRY1 (N) as positive when fluorescence intensity
(Alexa Fluor Plus 488) of PER2/CRY1 signal that overlapped with Hoechst 33342
signal was higher than the fluorescence intensity of PER2/CRY1 in the cytoplasm
Meanwhile, we interpreted a result for cytoplasmic localization of PER2/CRY1 (C)
as positive when PER2/CRY1 signal that did not overlap with Hoechst 33342
signal exhibited higher fluorescence intensity than PER2/CRY1 signal intensity that
overlapped with Hoechst 33342 signal. Finally, we interpreted a result for nuclear
and cytoplasm localization of PER2/CRY1 (N + C) as positive when PER2/CRY1
fluorescence signal at both nucleus and cytoplasm had the same intensities.
Supplementary Figure 2 | Confirmations of inhibitors by western blotting. (A)
NIH3T3 cells were treated with FK866 or EX-527 at indicated concentrations for
24 h. Total cell extracts were immunoblotted with antibodies against acetylated
form of BMAL1 (Ac-BMAL1) or BMAL1. (B) NIH3T3 cells were treated with 10 mM
NAM for 24 h. Total cell extracts from NIH3T3 (left and middle lanes) and mouse
embryonic fibroblast derived from Sirt1−/− without any treatment (right lane) were
immunoblotted with antibodies against acetylated form of BMAL1 (Ac-BMAL1) or
BMAL1. (C) NIH3T3 cells were treated with 10 µM PJ34 for 24 h. Total cell
extracts were immunoblotted with antibodies against poly ADP-ribosylation
(PAR/pADPr), PARP1 or TUBLIN.
Supplementary Figure 3 | GMX1778 decreases in NAD+ in cells. (A) NAD+
amount after 24 h treatment of GMX1778 at indicated concentrations were
measured by HPLC. NAD+ amount was normalized by protein amount. (B) NAD+
amount after 24 h treatment of 75 nM GMX1778 with or without 1mM NMN were
measured by HPLC. NAD+ amount was normalized by protein amount. (C)
Bmal1-luc oscillation patterns treated with GMX1778 with or without NMN were
monitored by using a real-time luciferase monitoring system. (D) Relative
amplitudes were analyzed. The value of control (ctrl) was set to 1. All data
represented in Supplementary Figure 3 are the mean ± SEM of independent
three samples. ∗∗p < 0.01 and ∗∗∗p < 0.001, compared to each of the untreated
control by Student’s two-tailed t-test, n.s., means not significant.
Supplementary Figure 4 | Effects of FK866 or GMX1778 on intracellular NAD+
amount. NIH3T3 were treated with NAMPT inhibitors, FK866 or GMX1778,
throughout this experiment.
Supplementary Figure 5 | FK866 has no effect on stabilities of clock proteins.
NIH3T3 cells expressing Myc-CLOCK (A), Myc-BMAL1 (B), Myc-PER2 (C), or
Myc-CRY1 (D) were treated with cycloheximide (CHX) at 100 µg/ml. At indicated
times, cells were lysed and protein extracts were immunoblotted with antibody to
Myc (top) and antibody to Tubulin (middle) as loading control. Cells were either
untreated (ctrl) or treated with 7.5 nM FK866. The results are representative of
three independent experiments. (Bottom) The immunoblots were quantified by
densitometric analysis. The graph shows the percentage of protein amount relative
to time 0 (100%). Myc-tagged proteins were normalized by each Tubulin amount.
Supplementary Figure 6 | FK866 has no effect on subcellular localizations of
CLOCK, BMAL1, RORα/γ and REV-ERVα/β. NIH3T3 cells expressing
Myc-CLOCK (A), Myc-BMAL1 (B), Flag-RORα (C), Flag-RORγ (D),
Flag-REV-ERBα (E), or Flag-REV-ERBβ (F) were immunostained with antibody to
Myc or DDDDK (top). Cells were untreated (ctrl), treated with 7.5 nM FK866 (FK) or
7.5 nM FK866 & 1 mM NMN (FK + NMN). The representative images were
captured by a confocal laser scanning microscope. (bottom) Subcellular
localizations were quantified; N, nucleus; C, cytoplasm; N + C, both nucleus and
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cytoplasm. White scale bars represent 100 µm. The data represented are the
mean ± SEM of three independent samples.
Supplementary Figure 7 | GMX1778 changes PER2 subcellular localization,
which is abrogated by co-treatment with NMN. (top) NIH3T3 cells expressing
indicated Myc-PER2 were immunostained with antibody to Myc. Cells were
untreated (ctrl), treated with 75 nM GMX1778 (GMX) or 75 nM GMX1778 & 1 mM
NMN (GMX + NMN). The representative images were captured by a confocal laser
scanning microscope. White scale bars represent 100 µm. (bottom) Subcellular
localizations were quantified; N, nucleus; C, cytoplasm; N + C, both nucleus and
cytoplasm. The data represented are the mean ± SEM of three independent
samples. ∗∗∗p < 0.001, compared to each subcellular localization in control cells
by Student’s two-tailed t-test.
Supplementary Figure 8 | CRY1 did not alter PER2 subcellular localization. (A)
Subcellular localizations of either PER2-WT, PER2-NLS, or PER2-NES were
quantified; N, nucleus; C, cytoplasm; N + C, both nucleus and cytoplasm. (B)
Subcellular localizations of either PER2-WT, PER2-NLS, or PER2-NES were
quantified when CRY1 was co-expressed. The data represented are the
mean ± SEM of three independent samples. ∗p < 0.05, ∗∗p < 0.01, and
∗∗∗p < 0.001, compared to each subcellular localization in cells expressing
PER2-WT by Student’s two-tailed t-test.
Supplementary Figure 9 | Sirt1 knockdown attenuates the amplitude of
Bmal1-luc oscillation. (A) Knockdown efficiencies against Sirt1 were analyzed by
qPCR. Sirt1 amount in control (scramble) was set to 1. The data represented are
the mean ± SEM of independent three samples. (B) Bmal1-luc oscillation patterns
in Sirt1 knockdown (shSirt1 #1 or #2) NIH3T3 cells were monitored by using a
real-time luciferase monitoring system. (C) Relative amplitudes were analyzed. The
value of control (ctrl) was set to 1. The data represented are the mean ± SEM of
independent 8, 3, or 3 samples for control, shSirt1 #1 or #2, respectively.
∗∗p < 0.01, compared to control cells by Student’s two-tailed t-test, n.s., means
not significant.
Supplementary Table 1 | Primer sequences for qPCR.
Supplementary Table 2 | Oligonucleotide sequences for knockdown
against Sirt1.
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